Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2024

Open Access 01-12-2024 | Insulins | Research

Association of the triglyceride-glucose index with all-cause and cardiovascular mortality in patients with cardiometabolic syndrome: a national cohort study

Authors: Quanjun Liu, Yeshen Zhang, Shuhua Chen, Hong Xiang, Jie Ouyang, Huiqin Liu, Jing Zhang, Yanfei Chai, Zishun Zhan, Peng Gao, Xiao Zhang, Jianing Fan, Xinru Zheng, Zhihui Zhang, Hongwei Lu

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Abstract

Objective

This study aimed to evaluate the association of triglyceride-glucose (TyG) index with all-cause and cardiovascular mortality risk among patients with cardiometabolic syndrome (CMS).

Methods

We performed a cohort study of 5754 individuals with CMS from the 2001–2018 National Health and Nutrition Examination Survey. The TyG index was calculated as Ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]. Multivariate Cox proportional hazards regression models assessed the associations between TyG index and mortality . Non-linear correlations and threshold effects were explored using restricted cubic splines and a two-piecewise Cox proportional hazards model.

Results

Over a median follow-up of 107 months, 1201 all-cause deaths occurred, including 398 cardiovascular disease-related deaths. The multivariate Cox proportional hazards regression model showed a positive association between the TyG index and all-cause and cardiovascular mortality. Each one-unit increase in the TyG index was associated with a 16% risk increase in all-cause mortality (HR: 1.16, 95% CI 1.03, 1.31, P = 0.017) and a 39% risk increase in cardiovascular mortality (HR: 1.39, 95% CI 1.14, 1.71, P = 0.001) after adjusting for confounders. The restricted cubic splines revealed a U-shaped association between the TyG index and all-cause (P for nonlinear < 0.001) and cardiovascular mortality (P for nonlinear = 0.044), identifying threshold values (all-cause mortality: 9.104; cardiovascular mortality: 8.758). A TyG index below these thresholds displayed a negative association with all-cause mortality (HR: 0.58, 95% CI 0.38, 0.90, P = 0.015) but not with cardiovascular mortality (HR: 0.39, 95% CI 0.12, 1.27, P = 0.119). Conversely, a TyG index exceeding these thresholds was positively associated with all-cause and cardiovascular mortality (HR: 1.35, 95% CI 1.17, 1.55, P < 0.001; HR: 1.54, 95% CI 1.25, 1.90, P < 0.001, respectively). Notably, a higher TyG index (≥ threshold values) was significantly associated with increased mortality only among individuals aged under 55 compared to those with a lower TyG index (< threshold values).

Conclusions

The TyG index demonstrated a U-shaped correlation with all-cause and cardiovascular mortality in individuals with CMS. The thresholds of 9.104 and 8.758 for all-cause and cardiovascular mortality, respectively, may be used as intervention targets to reduce the risk of premature death and cardiovascular disease.
Literature
2.
go back to reference Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The Lancet. 2005;365:1415–28.CrossRef Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The Lancet. 2005;365:1415–28.CrossRef
3.
go back to reference Wang Y, Mi J, Shan X-Y, Wang QJ, Ge K-Y. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond). 2007;31:177–88.PubMedCrossRef Wang Y, Mi J, Shan X-Y, Wang QJ, Ge K-Y. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond). 2007;31:177–88.PubMedCrossRef
4.
go back to reference Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Prev Chronic Dis. 2017;16(14):E24. Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Prev Chronic Dis. 2017;16(14):E24.
6.
go back to reference Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity (Silver Spring). 2006;14(Suppl 3):121S-127S.PubMed Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity (Silver Spring). 2006;14(Suppl 3):121S-127S.PubMed
7.
go back to reference Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, Bechara MD, Sloan KP, Sloan LA. Metabolic syndrome and cardiovascular diseases: going beyond traditional risk factors. Diabetes/Metab Res Rev. 2022;38:e3502.PubMedCrossRef Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, Bechara MD, Sloan KP, Sloan LA. Metabolic syndrome and cardiovascular diseases: going beyond traditional risk factors. Diabetes/Metab Res Rev. 2022;38:e3502.PubMedCrossRef
8.
go back to reference Guembe MJ, Fernandez-Lazaro CI, Sayon-Orea C, Toledo E, Moreno-Iribas C, RIVANA Study Investigators. Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort. Cardiovasc Diabetol. 2020;19:195.PubMedPubMedCentralCrossRef Guembe MJ, Fernandez-Lazaro CI, Sayon-Orea C, Toledo E, Moreno-Iribas C, RIVANA Study Investigators. Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort. Cardiovasc Diabetol. 2020;19:195.PubMedPubMedCentralCrossRef
9.
go back to reference Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.PubMedCrossRef Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.PubMedCrossRef
10.
go back to reference Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022;23:786.PubMedPubMedCentralCrossRef Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022;23:786.PubMedPubMedCentralCrossRef
11.
go back to reference Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3:1–58.PubMedPubMedCentral Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3:1–58.PubMedPubMedCentral
12.
go back to reference Gluvic Z, Zaric B, Resanovic I, Obradovic M, Mitrovic A, Radak D, et al. Link between metabolic syndrome and insulin resistance. Curr Vasc Pharmacol. 2017;15:30–9.PubMedCrossRef Gluvic Z, Zaric B, Resanovic I, Obradovic M, Mitrovic A, Radak D, et al. Link between metabolic syndrome and insulin resistance. Curr Vasc Pharmacol. 2017;15:30–9.PubMedCrossRef
13.
go back to reference Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119: 154766.PubMedCrossRef Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119: 154766.PubMedCrossRef
14.
go back to reference Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: past, present and future. Crit Rev Clin Lab Sci. 2015;52(4):180–90.PubMedCrossRef Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: past, present and future. Crit Rev Clin Lab Sci. 2015;52(4):180–90.PubMedCrossRef
15.
go back to reference Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–95.PubMedCrossRef Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–95.PubMedCrossRef
16.
go back to reference Son D-H, Lee HS, Lee Y-J, Lee J-H, Han J-H. Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. Nutr Metab Cardiovasc Dis. 2022;32:596–604.PubMedCrossRef Son D-H, Lee HS, Lee Y-J, Lee J-H, Han J-H. Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. Nutr Metab Cardiovasc Dis. 2022;32:596–604.PubMedCrossRef
17.
go back to reference Tao L-C, Xu J-N, Wang T-T, Hua F, Li J-J. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21:68.PubMedPubMedCentralCrossRef Tao L-C, Xu J-N, Wang T-T, Hua F, Li J-J. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21:68.PubMedPubMedCentralCrossRef
18.
go back to reference Tao S, Yu L, Li J, Xie Z, Huang L, Yang D, et al. Prognostic value of triglyceride-glucose index in patients with chronic coronary syndrome undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2023;22:322.PubMedPubMedCentralCrossRef Tao S, Yu L, Li J, Xie Z, Huang L, Yang D, et al. Prognostic value of triglyceride-glucose index in patients with chronic coronary syndrome undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2023;22:322.PubMedPubMedCentralCrossRef
19.
go back to reference Tao S, Yu L, Li J, Huang L, Huang X, Zhang W, et al. Association between the triglyceride-glucose index and 1-year major adverse cardiovascular events in patients with coronary heart disease and hypertension. Cardiovasc Diabetol. 2023;22(1):305.PubMedPubMedCentralCrossRef Tao S, Yu L, Li J, Huang L, Huang X, Zhang W, et al. Association between the triglyceride-glucose index and 1-year major adverse cardiovascular events in patients with coronary heart disease and hypertension. Cardiovasc Diabetol. 2023;22(1):305.PubMedPubMedCentralCrossRef
20.
go back to reference Zhang Q, Xiao S, Jiao X, Shen Y. The triglyceride-glucose index is a predictor for cardiovascular and all-cause mortality in CVD patients with diabetes or pre-diabetes: evidence from NHANES 2001–2018. Cardiovasc Diabetol. 2023;22(1):279.PubMedPubMedCentralCrossRef Zhang Q, Xiao S, Jiao X, Shen Y. The triglyceride-glucose index is a predictor for cardiovascular and all-cause mortality in CVD patients with diabetes or pre-diabetes: evidence from NHANES 2001–2018. Cardiovasc Diabetol. 2023;22(1):279.PubMedPubMedCentralCrossRef
21.
go back to reference Liu Q, Bai B, Liu F, Chen Y, Wang Y, Wang H, et al. Long-term trends in risk factor management in respondents with chronic kidney disease in the USA. Am J Nephrol. 2022;53:614–23.PubMedCrossRef Liu Q, Bai B, Liu F, Chen Y, Wang Y, Wang H, et al. Long-term trends in risk factor management in respondents with chronic kidney disease in the USA. Am J Nephrol. 2022;53:614–23.PubMedCrossRef
22.
go back to reference Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, American Heart Association, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.PubMedCrossRef Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, American Heart Association, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.PubMedCrossRef
23.
go back to reference Alizargar J, Bai C-H, Hsieh N-C, Wu SF-V. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol. 2020;19:8.PubMedPubMedCentralCrossRef Alizargar J, Bai C-H, Hsieh N-C, Wu SF-V. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol. 2020;19:8.PubMedPubMedCentralCrossRef
24.
go back to reference Navaneethan SD, Zoungas S, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023;176:381–7.PubMedCrossRef Navaneethan SD, Zoungas S, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023;176:381–7.PubMedCrossRef
25.
go back to reference Zhang Y-B, Chen C, Pan X-F, Guo J, Li Y, Franco OH, et al. Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: two prospective cohort studies. BMJ. 2021;373: n604.PubMedPubMedCentralCrossRef Zhang Y-B, Chen C, Pan X-F, Guo J, Li Y, Franco OH, et al. Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: two prospective cohort studies. BMJ. 2021;373: n604.PubMedPubMedCentralCrossRef
26.
go back to reference Tian Q, Huang D. Association between urinary IPM3 and the presence of cardio-cerebrovascular diseases: a cross-sectional study. Environ Sci Pollut Res Int. 2023;30:75817–22.PubMedCrossRef Tian Q, Huang D. Association between urinary IPM3 and the presence of cardio-cerebrovascular diseases: a cross-sectional study. Environ Sci Pollut Res Int. 2023;30:75817–22.PubMedCrossRef
27.
go back to reference Saint-Maurice PF, Graubard BI, Troiano RP, Berrigan D, Galuska DA, Fulton JE, et al. Estimated number of deaths prevented through increased physical activity among US adults. JAMA Intern Med. 2022;182:349–52.PubMedPubMedCentralCrossRef Saint-Maurice PF, Graubard BI, Troiano RP, Berrigan D, Galuska DA, Fulton JE, et al. Estimated number of deaths prevented through increased physical activity among US adults. JAMA Intern Med. 2022;182:349–52.PubMedPubMedCentralCrossRef
28.
go back to reference Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. JAMA. 2020;324:1190–200.PubMedCrossRef Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. JAMA. 2020;324:1190–200.PubMedCrossRef
29.
go back to reference Chen J, Wu K, Lin Y, Huang M, Xie S. Association of triglyceride glucose index with all-cause and cardiovascular mortality in the general population. Cardiovasc Diabetol. 2023;22:320.PubMedPubMedCentralCrossRef Chen J, Wu K, Lin Y, Huang M, Xie S. Association of triglyceride glucose index with all-cause and cardiovascular mortality in the general population. Cardiovasc Diabetol. 2023;22:320.PubMedPubMedCentralCrossRef
30.
go back to reference Li J, Dong Z, Wu H, Liu Y, Chen Y, Li S, et al. The triglyceride-glucose index is associated with atherosclerosis in patients with symptomatic coronary artery disease, regardless of diabetes mellitus and hyperlipidaemia. Cardiovasc Diabetol. 2023;22:224.PubMedPubMedCentralCrossRef Li J, Dong Z, Wu H, Liu Y, Chen Y, Li S, et al. The triglyceride-glucose index is associated with atherosclerosis in patients with symptomatic coronary artery disease, regardless of diabetes mellitus and hyperlipidaemia. Cardiovasc Diabetol. 2023;22:224.PubMedPubMedCentralCrossRef
31.
go back to reference Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum Á, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy Longev. 2023;4:e23-33.PubMedCrossRef Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum Á, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy Longev. 2023;4:e23-33.PubMedCrossRef
32.
go back to reference Meigs JB, Rutter MK, Sullivan LM, Fox CS, D’Agostino RB Sr, Wilson PWF. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30:1219–25.PubMedCrossRef Meigs JB, Rutter MK, Sullivan LM, Fox CS, D’Agostino RB Sr, Wilson PWF. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30:1219–25.PubMedCrossRef
33.
go back to reference Onat A, Hergenç G, Türkmen S, Yazici M, Sari I, Can G. Discordance between insulin resistance and metabolic syndrome: features and associated cardiovascular risk in adults with normal glucose regulation. Metabolism. 2006;55:445–52.PubMedCrossRef Onat A, Hergenç G, Türkmen S, Yazici M, Sari I, Can G. Discordance between insulin resistance and metabolic syndrome: features and associated cardiovascular risk in adults with normal glucose regulation. Metabolism. 2006;55:445–52.PubMedCrossRef
34.
go back to reference Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol. 2007;49:2112–9.PubMedCrossRef Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol. 2007;49:2112–9.PubMedCrossRef
35.
go back to reference Tahapary DL, Pratisthita LB, Fitri NA, Marcella C, Wafa S, Kurniawan F, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and Tryglyceride/glucose index. Diabetes Metab Syndr. 2022;16: 102581.PubMedCrossRef Tahapary DL, Pratisthita LB, Fitri NA, Marcella C, Wafa S, Kurniawan F, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and Tryglyceride/glucose index. Diabetes Metab Syndr. 2022;16: 102581.PubMedCrossRef
36.
go back to reference Molina MN, Ferder L, Manucha W. Emerging role of nitric oxide and heat shock proteins in insulin resistance. Curr Hypertens Rep. 2016;18:1.PubMedCrossRef Molina MN, Ferder L, Manucha W. Emerging role of nitric oxide and heat shock proteins in insulin resistance. Curr Hypertens Rep. 2016;18:1.PubMedCrossRef
37.
go back to reference Poon AK, Whitsel EA, Heiss G, Soliman EZ, Wagenknecht LE, Suzuki T, et al. Insulin resistance and reduced cardiac autonomic function in older adults: the atherosclerosis risk in communities study. BMC Cardiovasc Disord. 2020;20:217.PubMedPubMedCentralCrossRef Poon AK, Whitsel EA, Heiss G, Soliman EZ, Wagenknecht LE, Suzuki T, et al. Insulin resistance and reduced cardiac autonomic function in older adults: the atherosclerosis risk in communities study. BMC Cardiovasc Disord. 2020;20:217.PubMedPubMedCentralCrossRef
38.
go back to reference Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 2003;20:255–68.PubMedCrossRef Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 2003;20:255–68.PubMedCrossRef
39.
40.
go back to reference Godsland IF, Lecamwasam K, Johnston DG. A systematic evaluation of the insulin resistance syndrome as an independent risk factor for cardiovascular disease mortality and derivation of a clinical index. Metabolism. 2011;60:1442–8.PubMedCrossRef Godsland IF, Lecamwasam K, Johnston DG. A systematic evaluation of the insulin resistance syndrome as an independent risk factor for cardiovascular disease mortality and derivation of a clinical index. Metabolism. 2011;60:1442–8.PubMedCrossRef
41.
go back to reference US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, et al. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US preventive services task force recommendation statement. JAMA. 2020;324:2069–75.CrossRef US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, et al. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US preventive services task force recommendation statement. JAMA. 2020;324:2069–75.CrossRef
42.
go back to reference Ambrosy AP, Yang J, Sung SH, Allen AR, Fitzpatrick JK, Rana JS, et al. Triglyceride levels and residual risk of atherosclerotic cardiovascular disease events and death in adults receiving statin therapy for primary or secondary prevention: insights from the KP REACH study. J Am Heart Assoc. 2021;10: e020377.PubMedPubMedCentralCrossRef Ambrosy AP, Yang J, Sung SH, Allen AR, Fitzpatrick JK, Rana JS, et al. Triglyceride levels and residual risk of atherosclerotic cardiovascular disease events and death in adults receiving statin therapy for primary or secondary prevention: insights from the KP REACH study. J Am Heart Assoc. 2021;10: e020377.PubMedPubMedCentralCrossRef
43.
go back to reference Lee JH, Han K, Huh JH. The sweet spot: fasting glucose, cardiovascular disease, and mortality in older adults with diabetes: a nationwide population-based study. Cardiovasc Diabetol. 2020;19:44.PubMedPubMedCentralCrossRef Lee JH, Han K, Huh JH. The sweet spot: fasting glucose, cardiovascular disease, and mortality in older adults with diabetes: a nationwide population-based study. Cardiovasc Diabetol. 2020;19:44.PubMedPubMedCentralCrossRef
44.
go back to reference Li G, Zhong S, Wang X, Zhuge F. Association of hypoglycaemia with the risks of arrhythmia and mortality in individuals with diabetes—a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1222409.PubMedCrossRef Li G, Zhong S, Wang X, Zhuge F. Association of hypoglycaemia with the risks of arrhythmia and mortality in individuals with diabetes—a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1222409.PubMedCrossRef
45.
go back to reference Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24:353–63.PubMedCrossRef Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24:353–63.PubMedCrossRef
Metadata
Title
Association of the triglyceride-glucose index with all-cause and cardiovascular mortality in patients with cardiometabolic syndrome: a national cohort study
Authors
Quanjun Liu
Yeshen Zhang
Shuhua Chen
Hong Xiang
Jie Ouyang
Huiqin Liu
Jing Zhang
Yanfei Chai
Zishun Zhan
Peng Gao
Xiao Zhang
Jianing Fan
Xinru Zheng
Zhihui Zhang
Hongwei Lu
Publication date
01-12-2024
Publisher
BioMed Central
Keywords
Insulins
Insulins
Published in
Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-024-02152-y

Other articles of this Issue 1/2024

Cardiovascular Diabetology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine